Nicholls, Stephen J <br/><br/>
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.  [electronic resource] 

 -  Cardiovascular drugs and therapy  Feb 2012 
 - 71-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1573-7241 
<br/><br/><label>Standard No.: </label>10.1007/s10557-011-6358-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetates--therapeutic use<br/>Acute Coronary Syndrome--drug therapy<br/>Atorvastatin<br/>Double-Blind Method<br/>Heptanoic Acids--therapeutic use<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use<br/>Indoles--therapeutic use<br/>Inflammation--drug therapy<br/>Keto Acids<br/>Phospholipases A2, Secretory--antagonists & inhibitors<br/>Pyrroles--therapeutic use